Pier Paolo Pandolfi, M.D., Ph.D

Department of Pathology
Beth Israel Deaconess Medical Center
CLS Building, Room 401

330 Brookline Ave.
Boston, MA 02215
Tel: (617) 735-2161
Fax: (617) 735-2120
Email: ppandolf@bidmc.harvard.edu

The research carried out in our laboratory focuses on the molecular mechanisms and the genetics underlying the pathogenesis of human cancer as well as in modeling cancer in vivo in model systems such as the mouse. Throughout the years we have identified and functionally characterized major novel proto-oncogenes and tumor suppressors (e.g. PTEN, p53, PML and POKEMON). The elucidation of the molecular basis underlying tumor initiation, progression and metastasis has led to the development of novel and effective therapeutic concepts that are currently been utilized and tested in clinical trials.

References:

L.C. Trotman, A. Alimonti, P.P. Scaglioni, J.A. Koutcher, C. Cordon-Cardo and P.P. Pandolfi. Identification of a tumour suppressor network opposing nuclear Akt function. Nature, 441:523-7 2006.
R. Bernardi, I. Guernah, D. Jin, C. Cordon-Cardo, M. Celeste Simon, S. Rafii and P.P. Pandolfi. PML inhibits Hif-1? translation and neoangiogenesis through repression of mTOR. Nature, 442:779-785, 2006.
L.C. Trotman, X. Wang, A. Alimonti, Z. Chen, J. Teruya-Feldstein, S-G. Chi, H-J. Kim, H. Yang, N.P. Pavletich, B.S. Carver, H. Erdjument-Bromage, P. Tempst, C. Cordon-Cardo, T. Misteli. X. Jiang and P.P. Pandolfi. Ubiquitination regulates nuclear PTEN import and tumor suppression. Cell, 128:141-56, 2007.
T. Maeda, T. Merghoub, L. Dong, R.M. Hobbs, L. Dong, M. Maeda, J. Zakrzewski, M.R.M. van den Brink, A. Zelent, H. Shigematsu, K. Akashi, J. Teruya-Feldstein, G. Cattoretti and P.P. Pandolfi. Regulation of B versus T lymphoid lineage fate decision by the proto-oncogene LRF. Science, 316: 860-866, 2007.